Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada

International Journal of Drug Policy

Volumn 59, Issue , 2018, Pages 76-84

  Nouch, Susan ^a,b   Gallagher, Lesley ^a   Erickson, Margaret ^a,c   Elbaharia, Rabab ^a   Zhang, Wendy ^c   Wang, Lu ^c   Bacani, Nic ^c   Kason, Deborah ^a,b   Kleban, Holly ^a   Knebel, Laura ^a,b   Hall, David ^a,b   Barrios, Rolando ^a,b,c   Hull, Mark ^a,b,c  

^a VANCOUVER COASTAL HEALTH   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Daa; Hepatitis C; Injection drug use; Opioid agonist therapy; Primary care

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; OPIATE AGONIST; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ARTICLE; CANADA; CITY; COHORT ANALYSIS; COMMUNITY CARE; CONTROLLED STUDY; DEMOGRAPHY; DRUG DEPENDENCE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GENOTYPE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL; HUMAN; INTENTION TO TREAT ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK FACTOR; SUBSTANCE USE; SUSTAINED VIROLOGIC RESPONSE; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PRIMARY HEALTH CARE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; VIROLOGY;

ANTIVIRAL AGENTS; CANADA; CITIES; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 85050237415     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2018.06.019     Document Type: Article

References (37)

1. AASLD-IDSA, HCV guidance: Recommendations for testing, managing, and treating hepatitis C. 2018, HCV Guidelines.
2. Alavi, M., Raffa, J.D., Deans, G.D., Lai, C., Krajden, M., Dore, G.J., et al. Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents. Liver International 34:September (8) (2014), 1198–1206.
3. Asher, A.K., Portillo, C.J., Cooper, B.A., Dawson-Rose, C., Vlahov, D., Page, K.A., Clinicians’ views of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. Substance Use & Misuse 51:July (9) (2016), 1218–1223.
4. Baker, D., Alavi, M., Erratt, A., Hill, S., Balcomb, A., Hallinan, R., et al. Delivery of treatment for hepatitis C virus infection in the primary care setting. European Journal of Gastroenterology & Hepatology [Internet] 26:September (9) (2014), 1003–1009 Available from: https://www.ncbi.nlm.nih.gov/pubmed/25051216.
5. Barua, S., Greenwald, R., Grebely, J., Dore, G.J., Swan, T., Taylor, L.E., Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Annals of Internal Medicine (American College of Physicians) 163:August (3) (2015), 215–223.
6. Boglione, L., Mornese Pinna, S., De Nicolo, A., Cusato, J., Cariti, G., Di Perri, G., et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study. Journal of Viral Hepatitis 24:March (10) (2017), 850–857.
7. Brew, I.F., Butt, C., Wright, N., Can antiviral treatment for hepatitis C be safely and effectively delivered in primary care?. British Journal of General Practice 63:December (617) (2013), 842–851.
8. Butner, J.L., Gupta, N., Fabian, C., Henry, S., Shi, J.M., Tetrault, J.M., Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal of Substance Abuse Treatment 75:April (2017), 49–53.
9. Christensen, S., Buggisch, P., Mauss, S., Böker, K.H.W., Schott, E., Klinker, H., et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?. Addiction, 23(January (61)), 2018, S45.
10. Davis, G.L., Alter, M.J., El-Serag, H., Poynard, T., Jennings, L.W., Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology, 138(February (2)), 2010 513–521e1-6.
11. Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Global Health 5:December (12) (2017), e1192–207.
12. Dore, G.J., Altice, F., Litwin, A.H., Dalgard, O., Gane, E.J., Shibolet, O., et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial. Annals of Internal Medicine (American College of Physicians) 165:Nov (9) (2016), 625–634.
13. European Association for the Study of the Liver, EASL recommendations on treatment of hepatitis C 2018. Journal of Hepatology(April), 2018.
14. Grebely, J., Bryant, J., Hull, P., Hopwood, M., Lavis, Y., Dore, G.J., et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. Journal of Viral Hepatitis (Blackwell Publishing Ltd.) 18:April (4) (2011), e104–16.
15. Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. The International Journal on Drug Policy 26 (2015), 1028–1038.
16. Grebely, J., Dalgard, O., Conway, B., Cunningham, E.B., Bruggmann, P., Hajarizadeh, B., et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): An open-label, single-arm, phase 4, multicentre trial. The Lancet Gastroenterology & Hepatology(January (5)), 2018.
17. Jack, K., Willott, S., Manners, J., Varnam, M.A., Thomson, B.J., Clinical trial: A primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Alimentary Pharmacology & Therapeutics(January (1)), 2009 PubMed – NCBI. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+trial%3A+a+primary-care-based+model+for+the+delivery+of+anti-viral+treatment+to+injecting+drug+users+infected+with+hepatitis+C.
18. Janjua, N.Z., Chong, M., Kuo, M., Woods, R., Wong, J., Yoshida, E.M., et al. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Journal of Hepatology 66:March (3) (2017), 504–513.
19. Kattakuzhy, S., Gross, C., Emmanuel, B., Teferi, G., Jenkins, V., Silk, R., et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial. Annals of Internal Medicine 167:September (5) (2017), 311–318.
20. Lalezari, J., Sullivan, J.G., Varunok, P., Galen, E., Kowdley, K.V., Rustgi, V., et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology 63:August (2) (2015), 364–369.
21. Lynch, S.M., Wu, G.Y., Hepatitis C virus: A review of treatment guidelines, cost-effectiveness, and access to therapy. Journal of Clinical and Translational Hepatology (Xia & He Publishing Inc.) 4:December (4) (2016), 310–319.
22. Marshall, A.D., Saeed, S., Barrett, L., Cooper, C.L., Treloar, C., Bruneau, J., et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: A descriptive study. CMAJ Open (Canadian Medical Association) 4:Oct (4) (2016), E605–14.
23. Marshall, A.D., Cunningham, E.B., Nielsen, S., Aghemo, A., Alho, H., Backmund, M., et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. The Lancet Gastroenterology & Hepatology(October (3)), 2017.
24. Martin, N.K., Vickerman, P., Miners, A., Foster, G.R., Hutchinson, S.J., Goldberg, D.J., et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (Wiley Subscription Services, Inc., A Wiley Company) 55:January (1) (2012), 49–57.
25. Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58:November (5) (2013), 1598–1609.
26. Mason, K., Dodd, Z., Guyton, M., Tookey, P., Lettner, B., Matelski, J., et al. Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. International Journal of Drug Policy 12:June (47) (2017), 202–208.
27. Morris, L., Smirnov, A., Kvassay, A., Leslie, E., Kavanagh, R., Alexander, N., et al. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors’ Health Network. International Journal of Drug Policy 47:June (2017), 216–220.
28. Myers, R.P., Liu, M., Shaheen, A.A., The burden of hepatitis C virus infection is growing: A Canadian population-based study of hospitalizations from 1994 to 2004. Canadian Journal of Gastroenterology and Hepatology 22:April (4) (2008), 381–387.
29. Myers, R.P., Krajden, M., Bilodeau, M., Kaita, K., Marotta, P., Peltekian, K., et al. Burden of disease and cost of chronic hepatitis C infection in Canada. Canadian Journal of Gastroenterology and Hepatology (Hindawi Limited) 28:May (5) (2014), 243–250.
30. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Jarlais Des, D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 378:August (9791) (2011), 571–583.
31. Norton, B.L., Fleming, J., Bachhuber, M.A., Steinman, M., DeLuca, J., Cunningham, C.O., et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. International Journal of Drug Policy 47:September (2017), 196–201.
32. Patrick, D.M., Tyndall, M.W., Cornelisse, P.G., Li, K., Sherlock, C.H., Rekart, M.L., et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 165:October (7) (2001), 889–895.
33. Read, P., Lothian, R., Chronister, K., Gilliver, R., Kearley, J., Dore, G.J., et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. International Journal on Drug Policy(June (3)), 2017.
34. Rozada, I., Coombs, D., Lima, V.D., Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission. Journal of Theoretical Biology 21:April (395) (2016), 31–39.
35. Shah, H., Bilodeau, M., Burak, K.W., Cooper, C., Klein, M., Ramji, A., et al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 190:June (22) (2018), E677–87.
36. van der Meer, A.J., Veldt, B.J., Feld, J.J., Wedemeyer, H., Dufour, J.F., Lammert, F., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308:December (24) (2012), 2584–2593.
37. Woodrell, C., Weiss, J., Branch, A., Gardenier, D., Krauskopf, K., Kil, N., et al. Primary care-based hepatitis C treatment outcomes with first-generation direct-acting agents. Journal of Addiction Medicine 9:October (5) (2015), 405–410 PubMed – NCBI. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Primary+Care-Based+Hepatitis+C+Treatment+Outcomes+With+First-Generation+Direct-Acting+Agents.